[go: up one dir, main page]

IS5753A - Quinoline afleiður - Google Patents

Quinoline afleiður

Info

Publication number
IS5753A
IS5753A IS5753A IS5753A IS5753A IS 5753 A IS5753 A IS 5753A IS 5753 A IS5753 A IS 5753A IS 5753 A IS5753 A IS 5753A IS 5753 A IS5753 A IS 5753A
Authority
IS
Iceland
Prior art keywords
quinoline derivatives
quinoline
derivatives
Prior art date
Application number
IS5753A
Other languages
English (en)
Other versions
IS2187B (is
Inventor
Björk Anders
Jönsson Stig
Fex Tomas
Hedlund Gunnar
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IS5753A publication Critical patent/IS5753A/is
Publication of IS2187B publication Critical patent/IS2187B/is

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
IS5753A 1998-07-15 2000-12-05 Quinoline afleiður IS2187B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802550A SE9802550D0 (sv) 1998-07-15 1998-07-15 Quinoline derivatives
PCT/SE1999/001271 WO2000003992A1 (en) 1998-07-15 1999-07-14 Quinoline derivatives

Publications (2)

Publication Number Publication Date
IS5753A true IS5753A (is) 2000-12-05
IS2187B IS2187B (is) 2006-12-15

Family

ID=20412094

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5753A IS2187B (is) 1998-07-15 2000-12-05 Quinoline afleiður

Country Status (30)

Country Link
EP (1) EP1097139B1 (is)
JP (1) JP4082865B2 (is)
KR (1) KR100551611B1 (is)
CN (1) CN1114597C (is)
AP (1) AP1425A (is)
AT (1) ATE229005T1 (is)
AU (1) AU745915B2 (is)
BR (1) BR9912104B1 (is)
CA (1) CA2334718C (is)
DE (1) DE69904333T2 (is)
DK (1) DK1097139T3 (is)
EE (1) EE04276B1 (is)
ES (1) ES2187176T3 (is)
HR (1) HRP20010038A2 (is)
HU (1) HUP0103634A3 (is)
ID (1) ID27547A (is)
IL (1) IL140009A0 (is)
IS (1) IS2187B (is)
NO (1) NO317545B1 (is)
NZ (1) NZ508924A (is)
OA (1) OA11580A (is)
PL (1) PL200147B1 (is)
PT (1) PT1097139E (is)
RU (1) RU2213734C2 (is)
SE (1) SE9802550D0 (is)
TR (1) TR200100086T2 (is)
UA (1) UA70944C2 (is)
WO (1) WO2000003992A1 (is)
YU (1) YU1401A (is)
ZA (1) ZA200007493B (is)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SK4322003A3 (en) 2000-10-12 2003-09-11 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
ATE364385T1 (de) 2000-10-12 2007-07-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
DE60323743D1 (en) 2002-03-15 2008-11-06 Merck & Co Inc N-(substituierte benzyl)-8-hydroxy-1,6-naphthyridin-7- carbonsäureamide als hiv-integrase-hemmer
SE0201778D0 (sv) * 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
PL1937642T3 (pl) 2005-10-19 2015-02-27 Teva Pharma Kryształy lakwinimodu sodu i proces ich wytwarzania
KR20140091778A (ko) 2006-06-12 2014-07-22 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
PL2234485T3 (pl) 2007-12-20 2014-06-30 Teva Pharma Stabilne preparaty lakwinimodu
ES2633658T3 (es) 2008-09-03 2017-09-22 Teva Pharmaceutical Industries Ltd. Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
BR112012002124A2 (pt) 2009-07-30 2015-09-15 Teva Pharma tratamento da doença de crohn com laquinimode.
HRP20160997T1 (hr) 2009-08-10 2016-10-07 Teva Pharmaceutical Industries Ltd. Liječenje poremećaja povezanih s bdnf primjenom lakvinimoda
DK2542079T3 (da) 2010-03-03 2014-08-25 Teva Pharma Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
SG10201501535UA (en) 2010-03-03 2015-04-29 Teva Pharma Treatment of lupus nephritis using laquinimod
WO2012006538A1 (en) 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN103153959A (zh) 2010-10-14 2013-06-12 伊姆纳尔公司 作为AhR活化剂的1,2-二氢-4-羟基-2-氧代-喹啉-3-甲酰苯胺类
WO2013055907A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
SG11201404214QA (en) 2012-02-03 2014-08-28 Teva Pharma USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療gaba媒介之疾病之拉喹莫德(laquinimod)
HK1215210A1 (zh) 2012-11-07 2016-08-19 Teva Pharmaceutical Industries Ltd. 拉喹莫德胺盐
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN115836056A (zh) * 2020-05-21 2023-03-21 Stemsynergy疗法有限责任公司 Notch抑制剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE4120646A1 (de) * 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
SE469368B (sv) * 1991-10-09 1993-06-28 Kabi Pharmacia Ab Ny anvaendning av linomide foer tillverkning av laekemedel foer behandling av multiple sclerosis (ms)
CN1063686A (zh) * 1992-03-12 1992-08-19 华西医科大学药物研究所 用活性酯法合成维司力农
SE9201076L (sv) * 1992-04-06 1993-10-07 Shimon Slavin Användningen av gamla läkemedel för behandling av diabetes
JPH07224040A (ja) * 1994-02-07 1995-08-22 Fujisawa Pharmaceut Co Ltd キノリン誘導体
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9400809D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of quinoline-3-carboxamide compounds
SE9400810D0 (sv) * 1994-03-10 1994-03-10 Pharmacia Ab New use of Quinoline-3-carboxamide compounds
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives

Also Published As

Publication number Publication date
HUP0103634A2 (hu) 2002-02-28
PL345389A1 (en) 2001-12-17
YU1401A (sh) 2003-10-31
JP4082865B2 (ja) 2008-04-30
HK1035716A1 (en) 2001-12-07
ES2187176T3 (es) 2003-05-16
DK1097139T3 (da) 2002-12-30
KR20010071491A (ko) 2001-07-28
UA70944C2 (uk) 2004-11-15
DE69904333T2 (de) 2003-10-16
CA2334718C (en) 2006-11-21
CN1114597C (zh) 2003-07-16
IL140009A0 (en) 2002-02-10
WO2000003992A1 (en) 2000-01-27
JP2002520396A (ja) 2002-07-09
EE04276B1 (et) 2004-04-15
CN1309640A (zh) 2001-08-22
NO20010210D0 (no) 2001-01-12
AP1425A (en) 2005-06-06
HUP0103634A3 (en) 2002-03-28
HRP20010038A2 (en) 2001-12-31
SE9802550D0 (sv) 1998-07-15
ZA200007493B (en) 2001-06-19
AU745915B2 (en) 2002-04-11
CA2334718A1 (en) 2000-01-27
IS2187B (is) 2006-12-15
ATE229005T1 (de) 2002-12-15
BR9912104B1 (pt) 2010-07-13
ID27547A (id) 2001-04-12
EE200100007A (et) 2002-06-17
NO20010210L (no) 2001-03-15
OA11580A (en) 2004-07-01
TR200100086T2 (tr) 2001-05-21
EP1097139B1 (en) 2002-12-04
DE69904333D1 (de) 2003-01-16
KR100551611B1 (ko) 2006-02-13
PT1097139E (pt) 2003-04-30
EP1097139A1 (en) 2001-05-09
PL200147B1 (pl) 2008-12-31
NO317545B1 (no) 2004-11-15
BR9912104A (pt) 2001-05-02
RU2213734C2 (ru) 2003-10-10
AU5077599A (en) 2000-02-07
NZ508924A (en) 2002-09-27
AP2001002040A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
NO20013003D0 (no) Kinolin-derivater
ATE228505T1 (de) Chinolinderivate
ATE250036T1 (de) Chinolinderivate
ATE229005T1 (de) Chinolinderivate
DK1140935T3 (da) 1,2-anellerede quinolinderivater
NO20010193L (no) Tiobenzimidazol-derivater
DK0930302T3 (da) Benzosulfonderivater
DE69934788D1 (de) Biozide benzylbiphenylderivative
NO20010514D0 (no) Aminometylkarboksylsyre-derivater
ATE259810T1 (de) Phenyl-xanthinderivate
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
PT1056716E (pt) Derivados de ciclo-hexanodiolo
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
ATE281436T1 (de) Chinolin-4-yl-derivate
DK1060183T3 (da) 5-deoxycytidinderivater
PT1123283E (pt) Derivados de tiazole
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate